Literature DB >> 17312383

The activity of caspases in spontaneous and camptothecin-induced death of melanotic and amelanotic melanoma cell.

Miroslawa Cichorek1, Krystyna Kozłowska, Ewa Bryl.   

Abstract

Loss of pigment in hamster amelanotic melanoma line is accompanied by a faster growth rate, higher tumorigenicity and shorter animal survival time. Thus, the malignancy of melanoma increases during the alteration of melanotic (Ma) into amelanotic (Ab) line. As changes in the ability to undergo a spontaneous or induced apoptosis, and the role of caspases in this process during melanoma progression are not well defined, they were investigated in this work. Our results show that the proportion of spontaneously early apoptotic (caspase+/PI-) cells in the Ab line decreased in comparison to the Ma line. Cytochrome c release into cytosol, and the activation of effector caspases, estimated by PARP degradation clearly showed that during the spontaneous death in the cells from both melanoma lines intrinsic way of apoptosis was activated. Confocal and cytometric flow analyses indicate that camptothecin (CPT) induced apoptosis with caspase activation by the intrinsic way only in the amelanotic melanoma cells, even though cells of the Ma line also underwent CPT-induced apoptosis (the content of TUNEL-positive cells increased). Thus, our results suggest that melanoma progression, associated with a decreased ability to undergo spontaneous apoptosis but an increased susceptibility to CPT-induced apoptosis, relates to different levels of caspase activation; they also show that intrinsic way of apoptotis depends on the phenotype of melanoma cells, being more pronounced in the melanotic melanoma cells. On the other hand, melanotic melanoma cells resistance to camptothecin-induced apoptosis suggests that the melanogenic apparatus or melanin itself may have the protective effect on the ability of the melanoma cells to undergo apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17312383     DOI: 10.4161/cbt.6.3.3701

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  6 in total

1.  Melanin content in melanoma metastases affects the outcome of radiotherapy.

Authors:  Anna A Brożyna; Wojciech Jóźwicki; Krzysztof Roszkowski; Jan Filipiak; Andrzej T Slominski
Journal:  Oncotarget       Date:  2016-04-05

2.  CKS1 expression in melanocytic nevi and melanoma.

Authors:  Anna A Brożyna; Andrew Aplin; Cynthia Cohen; Grant Carlson; Andrew Joseph Page; Michael Murphy; Andrzej T Slominski; J Andrew Carlson
Journal:  Oncotarget       Date:  2017-12-23

Review 3.  Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship.

Authors:  Radomir M Slominski; Tadeusz Sarna; Przemysław M Płonka; Chander Raman; Anna A Brożyna; Andrzej T Slominski
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244

4.  Development and Validation of a Novel Survival Model for Cutaneous Melanoma Based on Necroptosis-Related Genes.

Authors:  Zehao Niu; Xin Wang; Yujian Xu; Yan Li; Xiaojing Gong; Quan Zeng; Biao Zhang; Jiafei Xi; Xuetao Pei; Wen Yue; Yan Han
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

5.  Pigmentation Levels Affect Melanoma Responses to Coriolus versicolor Extract and Play a Crucial Role in Melanoma-Mononuclear Cell Crosstalk.

Authors:  Małgorzata Pawlikowska; Tomasz Jędrzejewski; Andrzej T Slominski; Anna A Brożyna; Sylwia Wrotek
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

Review 6.  Transplantable Melanomas in Hamsters and Gerbils as Models for Human Melanoma. Sensitization in Melanoma Radiotherapy-From Animal Models to Clinical Trials.

Authors:  Martyna Śniegocka; Ewa Podgórska; Przemysław M Płonka; Martyna Elas; Bożena Romanowska-Dixon; Małgorzata Szczygieł; Michał A Żmijewski; Mirosława Cichorek; Anna Markiewicz; Anna A Brożyna; Andrzej T Słominski; Krystyna Urbańska
Journal:  Int J Mol Sci       Date:  2018-04-01       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.